Format

Send to

Choose Destination
See comment in PubMed Commons below
Dig Dis Sci. 2008 Jun;53(6):1455-61.

Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis.

Author information

1
Division of Gastroenterology and Hepatology, University of Calgary Health Sciences Centre, G 087, 3330 Hospital Drive, NW, Calgary, AB, Canada.

Abstract

BACKGROUND:

Published trials evaluating the efficacy of 6-thioguanine anti-metabolites in the treatment of ulcerative colitis (UC) have yielded conflicting results. We performed a systematic review and meta-analysis to evaluate the clinical efficacy of 6-thioguanine anti-metabolites for the maintenance of clinical remission after standard induction with corticosteroids.

METHODS:

A comprehensive search of online databases was conducted. Only randomized controlled trials with 6-thioguanine antimetabolites within a minimum duration of follow-up of 6 months were selected.

RESULTS:

Five trials were included in the meta-analysis. The pooled relative risk estimate for "success of treatment" with azathioprine (AZA) compared to 5-aminosalicylic acid or placebo was 1.42 [95% confidence interval (CI): 0.93-2.17, p = 0.109]; when only trials of a higher quality were used, a pooled relative risk estimate of 2.05 (95% CI: 1.30-3.23, p = 0.002) was obtained.

CONCLUSIONS:

Pooled results demonstrated a modest efficacy of AZA for the treatment of ulcerative colitis. However, the use of AZA for the management of UC is not based on high-quality evidence.

PMID:
17932752
DOI:
10.1007/s10620-007-0036-6
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Health
    Loading ...
    Support Center